Compare Ascendis Pharma A/S (ASND) vs Invesco S&P 500 Momentum ETF (SPMO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Invesco S&P 500 Momentum ETF — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Invesco S&P 500 Momentum ETF trades at $152.33. The key difference: Ascendis Pharma A/S is trading nearer its 52-week high, Invesco S&P 500 Momentum ETF nearer its low. Which is the better fit depends on your goals.
| ASND | SPMO | |
|---|---|---|
Market Cap | $17.74B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $277.18 | $161.66 |
52-Week Low | $163.32 | $107.84 |
Enterprise Value | $18.11B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
SPMO trades at $153.75, up 0.44% today, with a neutral technical signal. Momentum factor performance remains strong, gaining 7.5% in June 2026. The ETF's concentrated technology exposure (55%) drives returns but increases volatility. Support lies at $152, resistance at $155. Recent news highlights momentum's dominance in Q2 2026 with a 44.4% gain.
Outlook remains positive due to AI-driven momentum, though high sector concentration poses risks during market rotations. Analyst sentiment is generally bullish, but investors should monitor for signs of momentum fatigue or broader market pullbacks that could impact performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Invesco S&P 500 Momentum ETF
SPMO is designed to track the investment results of the S&P 500 Momentum Index. This index measures the performance of stocks in the S&P 500 that exhibit the highest momentum, or the greatest price appreciation, over the trailing 12 months, while excluding the most recent month. By investing in these high-momentum stocks, SPMO seeks to capitalize on the historical trend that stocks with strong recent performance tend to continue that performance in the near term, offering a systematic approach to factor investing within the large-cap U.S. equity market.
Read more on SPMO →
